• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌肺转移患者使用乐伐替尼后出现肺出血和气胸血胸。

Pulmonary hemorrhage and hemopneumothorax following the administration of lenvatinib for lung metastasis from hepatocellular carcinoma.

作者信息

Kishimoto Kazuya, Izumi Nobuhiro, Kinoshita Hirotaka, Tanimura Takuya, Suzuki Satoshi, Hara Kantaro, Inoue Hidetoshi, Tsukioka Takuma, Shiohara Masanori, Odagiri Naoshi, Soh Junichi

机构信息

Department of Thoracic Surgery, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

出版信息

Respir Med Case Rep. 2025 May 13;56:102233. doi: 10.1016/j.rmcr.2025.102233. eCollection 2025.

DOI:10.1016/j.rmcr.2025.102233
PMID:40488208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12145532/
Abstract

A 71-year-old man was started on 12 mg/day of lenvatinib for lung metastasis from hepatocellular carcinoma (HCC). The day after starting treatment, he developed hemoptysis, and a CT scan revealed a rupture of the left upper lobe metastasis, accompanied by pulmonary hemorrhage. Angiography was performed, and the responsible blood vessels, the bronchial artery and the left pulmonary artery (A1+2ab), were embolized. One week later, the patient developed a left tension pneumothorax. Despite thoracic drainage, air leakage and bloody drainage persisted. We decided to perform a left upper lobe resection to control the bleeding and air leakage. A 10-cm necrotic lesion was found in the left upper lobe, and the pleura between the lobes had ruptured, causing a hematoma to drain into the pleural cavity. We encountered a case of hemopneumothorax resulting from the rupture of lung metastases from HCC during treatment with lenvatinib.

摘要

一名71岁男性因肝细胞癌(HCC)肺转移开始接受每日12毫克乐伐替尼治疗。开始治疗后的第二天,他出现咯血,CT扫描显示左上叶转移灶破裂,并伴有肺出血。进行了血管造影,并对责任血管,即支气管动脉和左肺动脉(A1+2ab)进行了栓塞。一周后,患者出现左侧张力性气胸。尽管进行了胸腔引流,但仍持续存在漏气和血性引流。我们决定进行左上叶切除术以控制出血和漏气。在左上叶发现一个10厘米的坏死病灶,并发现叶间胸膜破裂,导致血肿流入胸腔。我们遇到了一例在乐伐替尼治疗期间HCC肺转移灶破裂导致血气胸的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/c60d5edea962/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/e0dfa4716359/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/a440d5dcbaf6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/78727cb6c6dd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/f5c5121daa7f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/c60d5edea962/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/e0dfa4716359/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/a440d5dcbaf6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/78727cb6c6dd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/f5c5121daa7f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5618/12145532/c60d5edea962/gr5.jpg

相似文献

1
Pulmonary hemorrhage and hemopneumothorax following the administration of lenvatinib for lung metastasis from hepatocellular carcinoma.肝细胞癌肺转移患者使用乐伐替尼后出现肺出血和气胸血胸。
Respir Med Case Rep. 2025 May 13;56:102233. doi: 10.1016/j.rmcr.2025.102233. eCollection 2025.
2
Spontaneous hemopneumothorax after laparoscopy: a case report and literature review.腹腔镜检查术后自发性血气胸:一例病例报告及文献综述
J Int Med Res. 2020 Jul;48(7):300060520925322. doi: 10.1177/0300060520925322.
3
Spontaneous hemopneumothorax with a ruptured aneurysm in the second intercostal artery: report of a case.自发性血气胸伴第二肋间隙动脉破裂性动脉瘤:病例报告。
Gen Thorac Cardiovasc Surg. 2021 Jul;69(7):1133-1136. doi: 10.1007/s11748-021-01620-6. Epub 2021 May 27.
4
Spontaneous hemopneumothorax causing life-threatening hemorrhage: a case report.自发性血气胸导致危及生命的出血:一例报告
J Med Case Rep. 2024 Aug 7;18(1):375. doi: 10.1186/s13256-024-04715-9.
5
[A case of spontaneous hemopneumothorax occurred after thoracic drainage].[胸腔引流后发生自发性血气胸1例]
Kyobu Geka. 1998 Oct;51(11):970-3.
6
Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report.用乐伐替尼治疗肝细胞癌支气管内转移:一例报告
Respirol Case Rep. 2023 Aug 22;11(9):e01208. doi: 10.1002/rcr2.1208. eCollection 2023 Sep.
7
Lenvatinib treatment strategy for thyroid carcinoma with malignant pleurisy: a case report.乐伐替尼治疗伴恶性胸膜炎的甲状腺癌的策略:一例报告
Gland Surg. 2024 Oct 31;13(10):1846-1852. doi: 10.21037/gs-24-269. Epub 2024 Oct 26.
8
[Nine cases of spontaneous hemopneumothorax with massive bleeding].
Kyobu Geka. 1996 Mar;49(3):199-201.
9
Pericardial fat pad plombage for pulmonary cavity causing massive air leakage.心包脂肪垫充填术治疗导致大量漏气的肺空洞。
Surg Case Rep. 2020 Jul 1;6(1):156. doi: 10.1186/s40792-020-00917-7.
10
Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.仑伐替尼起始化疗后不久导致肝癌破裂引起的腹腔内出血两例。
Intern Med. 2022 Aug 1;61(15):2301-2305. doi: 10.2169/internalmedicine.8733-21. Epub 2022 Mar 12.

本文引用的文献

1
Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis.在使用仑伐替尼治疗伴有肺转移的肝细胞癌时发生气胸。
Clin J Gastroenterol. 2021 Feb;14(1):288-292. doi: 10.1007/s12328-020-01273-7. Epub 2020 Oct 27.
2
Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers.乐伐替尼:一种用于多种癌症的有前景的分子靶向药物。
Cancer Control. 2018 Jan-Dec;25(1):1073274818789361. doi: 10.1177/1073274818789361.
3
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较:一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
4
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.乐伐替尼是一种靶向VEGFR/FGFR的血管生成抑制剂,在与微血管密度和周细胞覆盖相关的人肿瘤异种移植模型中显示出广泛的抗肿瘤活性。
Vasc Cell. 2014 Sep 6;6:18. doi: 10.1186/2045-824X-6-18. eCollection 2014.
5
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.血管内皮生长因子酪氨酸激酶抑制剂治疗癌症患者的治疗相关死亡率的发生率和风险的随机对照试验的荟萃分析。
J Clin Oncol. 2012 Mar 10;30(8):871-7. doi: 10.1200/JCO.2011.37.1195. Epub 2012 Feb 6.
6
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.血管内皮生长因子受体酪氨酸激酶抑制剂舒尼替尼和索拉非尼的出血风险:一项临床试验的系统评价和荟萃分析
Lancet Oncol. 2009 Oct;10(10):967-74. doi: 10.1016/S1470-2045(09)70222-0. Epub 2009 Sep 18.
7
Spontaneous rupture of hepatocellular carcinoma and vascular injury.肝细胞癌自发性破裂与血管损伤
Arch Surg. 2001 Jun;136(6):682-7. doi: 10.1001/archsurg.136.6.682.